BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 11, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2011

View Archived Issues

Abciximab combined with heparin may be useful to treat stroke

Read More

Omeros identifies compounds that interact with GPCRs linked to metabolic and psychotic disorders

Read More

Solvay's SLV-338 alleviates symptoms of pulmonary hypertension in vivo

Read More

Novel MEK 1 inhibitors synthesized at Novartis

Read More

Athersys reports interim data from ongoing phase I MultiStem study

Read More

Preliminary phase III data presented at ASCO on bosutinib versus imatinib in Ph+ CML

Read More

Proactivator polypeptide described as new biomarker in prostate cancer

Read More

New data disclosed on duloxetine in chronic depression, MDD and GAD

Read More

Gilead presents new voltage-gated Na(V)1.5 sodium channel blockers

Read More

Novadex Pharmaceuticals discloses novel renin inhibitors

Read More

Grindeks claims new cognition-enhancing piracetam derivative enantiomer

Read More

New ghrelin receptor antagonists and/or inverse agonists synthesized

Read More

Novel 9-aminoacridine derivatives for cancer presented

Read More

Immunovaccine's phase I DPX-0907 trial meets primary objective

Read More

Asimadoline receives FDA fast track status for diarrhea-predominant irritable bowel syndrome

Read More

Ono and Daninippon Sumitomo to codevelop limaprost for carpal tunnel syndrome

Read More

Recruitment begins in phase Ib Ampion trial in osteoarthritis of the knee

Read More

Phase III data reported on CVT-E002 for acute respiratory illness in chronic lymphocytic leukemia

Read More

Aastrom's RESTORE-CLI trial meets primary safety and efficacy endpoints

Read More

Week 56 data consistent with earlier results in phase III lomitapide trial in HoFH

Read More

Kyowa Hakko Kirin and Valeant terminate North American licensing agreement for KW-6002

Read More

Bristol-Myers Squibb and Roche enter agreement to evaluate ipilimumab/vemurafenib combination

Read More

AVEO and Centocor Ortho Biotech enter license agreement for antibodies targeting MSP receptor

Read More

Lpath reports encouraging preclinical data on Lpathomab

Read More

GSK and Theravance provide results from two pivotal phase III Relovair trials in COPD

Read More

FDA finds no evidence of increased risk of cancer in safety review of ARBs

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 9, 2026
  • 3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

    Skape Bio unlocks GPCR targets with de novo-designed miniproteins

    BioWorld
    Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
  • Wuxi Apptec signage

    Wuxi Apptec insists it’s ‘not a Chinese military company’

    BioWorld
    Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
  • Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

    BioWorld Science
    Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing